Clinical Trial Update: AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating AK104 in combination with chemotherapy as neoadjuvant treatment for advanced ovarian cancer is ongoing, with status not spec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Ovarian Cancer | Phase 2 | Status: UNKNOWN